Rolph Timothy's Form 4/A amendment
AmendedAkero Therapeutics, Inc. (AKRO) · filed Oct 27, 2022
- Accession no.
- 0000899243-22-034368
- Filed
- Oct 27, 2022
- Trade date
- Sep 13, 2022
- Filing delay
- 44 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Sep 15, 2022
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $656.5K. It was filed 44 days after the trade.
This amendment replaces 0000899243-22-031196 (filed Sep 15, 2022).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rolph TimothyCIK 0001779479 | Officer (Chief Scientific Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 13, 2022 | Common Stock | MOption exerciseAcquired | +10,000 | $6.36 | +$63,600 | 256,337 | Direct | |
| Sep 13, 2022 | Common Stock | SSaleDisposed | −22,500 | $29.18F3 | −$656,550 | 233,837 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 13, 2022 | Common Stock | MOption exerciseDisposed | −10,000 | $0.00 | $0 | 62,756 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On September 15, 2022, the reporting person filed a Form 4 which inadvertently omitted the exercise of 10,000 options by the reporting person. The shares of Common Stock underlying those options were subsequently sold pursuant to a Rule 10b5-1 trading plan as reported in the original Form 4. This amendment to the original Form 4 is being filed solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock.
- F2
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated June 25, 2021, previously adopted by the reporting person.
- F3
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.39, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F4
This option shall vest and become exercisable in 48 equal monthly installments, commencing on January 1, 2019.